Linked Life Data

8435663

Source:http://linkedlifedata.com/resource/pubmed/id/8435663

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1993-3-25
pubmed:abstractText
In August 1988 we began a program in which multiple myeloma patients achieving < or = 10% marrow plasma cells and > or = 50% reduction in paraprotein levels after the VAD (vincristine, doxorubicin, dexamethasone) regimen underwent bone marrow harvest, ex vivo marrow purging with 4-hydroperoxycyclophosphamide (4-HC) and marrow cryopreservation. Conditioning with a regimen of high-dose busulfan (total dose 16 mg/kg), cyclophosphamide (120 mg/kg) and melphalan (90 mg/m2) (BU + CY + MEL) followed by autologous BMT was then carried out. Seventeen of the 24 patients who received VAD (71%, 95% confidence interval [CI] 49 to 87%) were eligible for bone marrow harvest. One patient was not harvested because of non-medical reasons; two patients who underwent marrow harvest had gross plasmacytosis present in biopsies performed intraoperatively and did not undergo BMT. Fourteen patients (58%, 95% CI 37 to 78%) received BU + CY + MEL and 4-HC-purged autologous BMT. The median time to recovery of 0.5 x 10(9)/l neutrophils was 19 days (range 14 to 26) while the last platelet transfusion was given on a median of day 32 (range 10 to 46) post-BMT in the evaluable patients. The major non-hematologic toxicity was hepatic; two patients in complete remission died of hepatic veno-occlusive disease. Another patient succumbed to fungal infection despite neutrophil recovery. The remaining 11 patients achieved responses (complete in six and partial in five) associated with a normal performance status.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
139-46
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:8435663-Adult, pubmed-meshheading:8435663-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:8435663-Bone Marrow Purging, pubmed-meshheading:8435663-Bone Marrow Transplantation, pubmed-meshheading:8435663-Busulfan, pubmed-meshheading:8435663-Clinical Protocols, pubmed-meshheading:8435663-Combined Modality Therapy, pubmed-meshheading:8435663-Cyclophosphamide, pubmed-meshheading:8435663-Cytarabine, pubmed-meshheading:8435663-Dexamethasone, pubmed-meshheading:8435663-Female, pubmed-meshheading:8435663-Humans, pubmed-meshheading:8435663-Life Tables, pubmed-meshheading:8435663-Male, pubmed-meshheading:8435663-Melphalan, pubmed-meshheading:8435663-Middle Aged, pubmed-meshheading:8435663-Multiple Myeloma, pubmed-meshheading:8435663-Survival Analysis, pubmed-meshheading:8435663-Transplantation, Autologous, pubmed-meshheading:8435663-Vincristine
pubmed:year
1993
pubmed:articleTitle
Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
pubmed:affiliation
Leukemia/Bone Marrow Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Canada.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't